Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HTR3A | P46098 | 3/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.42 |
| ▸ | HTR3B | O95264 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL356141 | 0.86 | TNF (0.47) | LMNAMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL944723 | 0.85 | TDP1 (0.51) | RAB9ATBXA2RLMNAMAPTMEN1 | |
| SCHEMBL9696659 | 0.84 | GRM2 (0.46) | RAB9AMAPTMEN1ALDH1A1HTT | |
| SCHEMBL2541667 | 0.80 | HTT (0.52) | RAB9AHTR3ATBXA2RLMNAMAPT | |
| SCHEMBL9695569 | 0.78 | TP53 (0.44) | HTR3AHTR3EHTR3BHTR1AHTR2C | |
| SCHEMBL945956 | 0.74 | TNF (0.50) | RAB9ALMNAMAPTMEN1ALDH1A1 | |
| SCHEMBL1381878 | 0.72 | SLC9A1 (0.44) | RAB9ALMNAMAPTMEN1ALDH1A1 | |
| SCHEMBL2103982 | 0.72 | POLB (0.39) | LMNAMAPTALDH1A1TSHRHTT | |
| SCHEMBL5000372 | 0.70 | MAPT (0.38) | MAPTALDH1A1HTTSMN1; SMN2CYP2D6 | |
| SCHEMBL1300677 | 0.70 | MAPT (0.50) | RAB9AHTR3ALMNAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014783-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-22 | — | — | US | claimed |
| US-20040006080-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-08 | — | — | US | claimed |
| CN-1433411-A | Compound (I) | ASTRAZENECA AB (SE) | 2003-07-30 | — | — | CN | claimed |
| EP-1274701-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-01-15 | — | — | EP | claimed |
| US-20020077337-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2002-06-20 | — | — | US | claimed |
| WO-2001077101-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-10-18 | — | — | WO | claimed |
| US-5283243-A | Anti-inflammatory, anti-allergic, hypotensive and vasodilating agents | KALI-CHEMIE PHARMA GMBH (DE) | 1994-02-01 | — | — | US | claimed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| EP-1493743-B1 | Substituted bipiperidine intermediates and derivatives thereof | ASTRAZENECA AB (SE) | 2008-09-03 | — | — | EP | disclosed |
| US-20070179297-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-08-02 | — | — | US | disclosed |
| US-7238811-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-03 | — | — | US | disclosed |
| US-7179922-B2 | 4-Phenyloxypiperidionopiperidine compounds as antiinflammatory agents; autoimmune diseases; rheumatic diseases; cardiovascular disorders | ASTRAZENECA AB (SE) | 2007-02-20 | — | — | US | disclosed |
| CN-1244576-C | Compound (I) | ASTRAZENECA AB (SE) | 2006-03-08 | — | — | CN | disclosed |
| CN-1202894-A | Substituted 4-(1H-benzimidzol-2-yl-amino) piepridines useful for the treatment of allergic diseases | HOECHST MARION ROUSSEL INC (US) | 1998-12-23 | — | — | CN | disclosed |
| WO-1997030989-A1 | NOVEL SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL-AMINO)PIPERIDIN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1997-08-28 | — | — | WO | disclosed |
| WO-1997019074-A1 | SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL-AMINO)PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1997-05-29 | — | — | WO | disclosed |
| CN-1028103-C | Preparation method of piperidyl benzimidazole compound | MERRELL DOW PHARMA (US) | 1995-04-05 | — | — | CN | disclosed |
| US-5283243-A | Anti-inflammatory, anti-allergic, hypotensive and vasodilating agents | KALI-CHEMIE PHARMA GMBH (DE) | 1994-02-01 | — | — | US | disclosed |
| WO-1992006086-A1 | NOVEL 4-PIPERIDINYLCARBONYL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-04-16 | — | — | WO | disclosed |
| CN-1041940-A | PIPERIDINYL BENZIMIDAZOLES | MERRELL DOW PHARMA (US) | 1990-05-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077337-A1 | Chemical compounds | CCR3, CCR1, CCR4 | RAB9A 2344/4885HTR3A 392/4885HTR3E 372/4885 |
| US-20040006080-A1 | Chemical compounds | CCR3, CCR1, CCR4 | RAB9A 2344/4885HTR3A 392/4885HTR3E 372/4885 |
| US-20040014783-A1 | Chemical compounds | CCR3, CCR1, CCR4 | RAB9A 2344/4885HTR3A 392/4885HTR3E 372/4885 |
| US-20070179297-A1 | Chemical compounds | CCR3, CCR1, CCR4 | RAB9A 2189/4885HTR3A 393/4885HTR3E 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.